A new vaccine to protect children from respiratory viruses.
Official title: A parainfluenza virus 5 (PIV5)-based bivalent vaccine for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV)
Funded at Cyanvac, LLC · NIH-10920481 · Data updated 2026-11-12
This study is testing a new nose spray vaccine that could help protect young children from serious respiratory infections caused by RSV and HMPV, making it easier for them to stay healthy and breathe better.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cyanvac, LLC NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project start | September 5, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $201,900 |
| NIH project number | 5R21AI175677-02 |
| Project ID | NIH-10920481 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children under the age of 10, particularly those at risk for severe respiratory infections.
✕Less likely to help
Patients who are older than 10 years or those with existing severe respiratory conditions may not benefit from this research.
What this research studies
This research focuses on developing a safe and effective intranasal vaccine using parainfluenza virus 5 (PIV5) to protect against respiratory syncytial virus (RSV) and human metapneumovirus (HMPV). These viruses are major causes of respiratory infections in young children, leading to serious conditions like bronchiolitis and pneumonia. The vaccine aims to stimulate the immune system to produce antibodies against both viruses, potentially reducing the incidence of severe respiratory illnesses in children. The approach is novel as it combines immunogenic components from both viruses into a single vaccine, which is administered through the nose for easier delivery.
Why it matters
Potential benefit: If successful, this research could lead to a new vaccine that significantly reduces respiratory infections in children.
How similar studies have gone: Previous research has shown promise in developing vaccines using similar viral vectors, indicating potential for success in this approach.
Where this research is happening
-
Cyanvac, LLC
Athens, United States Active
Researchers
- Principal investigator: Gingerich, Maria Cristina — Cyanvac, LLC
- Study coordinator: Gingerich, Maria Cristina
Related research
Other NIH-funded projects on the same topics.
-
RSV vaccine safety and immune response in lung transplant patients vs. healthy adults
This study tests how well the RSV vaccine works and how safe it is in people who have had a lung transplant compared with healthy adults.
-
RSV vaccine in children at high risk to see if it is safe and makes a strong immune response
This study tests whether the RSVpreF vaccine is safe and helps the immune system in children aged 5 to under 18 who are at high risk for RSV illness, including those who are immunocompromised.
-
Revaccination with RSVpreF in Immunocompromised Adults
This study tests whether giving an RSVpreF vaccine shot again at about 1, 2, and 3 years is safe and can still provoke an immune response in adults who are immunocompromised.
-
Vaccine candidates for RSV and hMPV in older adults
This study tests whether mRNA-1365 and related vaccine profiles are safe and able to trigger an immune response in healthy older adults.
-
YKYY025 Injection safety and immune response test in adults
This phase 1 study tests whether YKYY025 is safe and prompts an immune response in healthy adults.
-
RSVpreF vaccine in adults: safety and immune response in India
A Phase 3 test of the RSVpreF vaccine vs placebo in adults 18 and older living in India to see if it is safe and produces an immune response.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.